Abstract
Background Despite eradication efforts, ∼135,000 African children sustained brain injuries as a result of central nervous system (CNS) malaria in 2021. Newer antimalarial medications rapidly clear peripheral parasitemia and improve survival, but mortality remains high with no associated decline in post-malaria neurologic injury. A randomized controlled trial of aggressive antipyretic therapy with acetaminophen and ibuprofen (Fever RCT) for malarial fevers being conducted in Malawi and Zambia began enrollment in 2019. We propose to use neuroimaging in the context of the RCT to further evaluate neuroprotective effects of aggressive antipyretic therapy.
Methods This observational magnetic resonance imaging (MRI) ancillary study will obtain neuroimaging and neurodevelopmental and behavioral outcomes in children previously enrolled in the Fever RCT at 1- and 12-months post discharge. Analysis will compare the odds of any brain injury between the aggressive antipyretic therapy and usual care groups based upon MRI structural abnormalities. For children unable to undergo imaging without deep sedation, neurodevelopmental and behavioral outcomes will be used to identify brain injury.
Discussion Neuroimaging is a well-established, valid proxy for neurological outcomes after brain injury in pediatric CNS malaria. This MRI ancillary study will add value to the Fever RCT by determining if treatment with aggressive antipyretic therapy is neuroprotective in CNS malaria. It may also help elucidate the underlying mechanism(s) of neuroprotection and expand upon FEVER RCT safety assessments.
Competing Interest Statement
Moses Chilombe has no disclosures. Karl B. Seydel has received funding from the US NIH. Colleen Hammond has no disclosures. Suzanna Mwanza has not disclosures. Archana Patel -has received funding from the US NIH.. Frank Lungu has no disclosures. Somwe wa Somwe has no disclosures. Sam Kampondeni has no disclosures. Michael J. Potchen has received funding. from the US NIH and is a paid medical legal consultant on work unrelated to the research presented here. Gretchen L. Birbeck has received funding from the US NIH and is a paid consultant for BlueSpark Technologies.
Funding Statement
GB received the award: R01NS111057 and R35NS122265 KBS received the award: R35NS122265 The study was funded by the US National Institute of Health NIH Grant No. R01NS111057 and R35NS122265 https://www.ninds.nih.gov/ The funders had no role in study design, data collection, data analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study has been approved by the following Institutional Review Boards: The University of Zambia's Biomedical Research Ethics Committee FWA00000338 (UNZA BREC)-approved on 3 Nov 2020, approval number Ref No. 1186-2020 The University of Malawi's College of Medicine Research Ethics Committee FWA00011868 (COMREC)-initially approved on 16 Sep 2020, approval number P.06/20/3070 The University of Rochester's Research Subjects Review Board FWA00009386 (RSRB) - initially approved 01 Dec 2020, approval number RSRB 00005384 Written informed consent from the parent/guardian will be required for enrollment.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
No datasets were generated or analysed during the current study.
Abbreviations
- BMPES
- Blantyre Malaria Project Epilepsy Study
- CNS
- central nervous system
- CM
- Cerebral Malaria
- MRI
- Magnetic Resonance Imaging
- MSU
- Michigan State University
- RCT
- randomized controlled trial.
- RSRB
- The University of Rochester’s Research Subjects Review Board
- Tmax
- maximum temperature
- PI
- Principal Investigator
- UNZA BREC
- The University of Zambia’s Biomedical Research Ethics Committee
- UR
- University of Rochester
- UNZA BREC
- The University of Zambia’s Biomedical Research Ethics Committee
- UTH
- University Teaching Hospital
